<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6060540</article-id><article-id pub-id-type="doi">10.3389/fendo.2018.00398</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Case Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Medullary Thyroid Carcinoma With Exon 2 p.L56M RET Variant: Clinical Particular Features in Two Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Paragliola</surname><given-names>Rosa M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lovicu</surname><given-names>Rosa M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Papi</surname><given-names>Giampaolo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/158302/overview"/></contrib><contrib contrib-type="author"><name><surname>Capoluongo</surname><given-names>Ettore</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Minucci</surname><given-names>Angelo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/585476/overview"/></contrib><contrib contrib-type="author"><name><surname>Canu</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pontecorvi</surname><given-names>Alfredo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/21629/overview"/></contrib><contrib contrib-type="author"><name><surname>Corsello</surname><given-names>Salvatore M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/550776/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Unit of Endocrinology, Universit&#x000e0; Cattolica del Sacro Cuore</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>Unit of Biochemistry and Clinical Biochemistry, F. Policlinico Gemelli IRCCS, Universit&#x000e0; Cattolica del Sacro Cuore</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Giorgio Stassi, Universit&#x000e0; degli Studi di Palermo, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Agnese Barnabei, Istituto Nazionale del Cancro Regina Elena, Italy; Dario Giuffrida, Istituto Oncologico del Mediterraneo, Italy; Pasqualino Malandrino, Department of Clinical and Experimental Medicine, Italy</p></fn><corresp id="c001">*Correspondence: Salvatore M. Corsello <email>salvatore.corsello@unicatt.it</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology</p></fn></author-notes><pub-date pub-type="epub"><day>19</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>398</elocation-id><history><date date-type="received"><day>27</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Paragliola, Lovicu, Papi, Capoluongo, Minucci, Canu, Pontecorvi and Corsello.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Paragliola, Lovicu, Papi, Capoluongo, Minucci, Canu, Pontecorvi and Corsello</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>RET (REarranged during Transfection) proto-oncogene variants are essential for the development of familial and sporadic forms of medullary thyroid carcinoma (MTC). The most frequent variants are usually located in exons 10, 11, and 13 through 16 of the RET gene. We report two cases of apparently sporadic MTC associated with the variant in exon 2 of <italic>RET</italic> gene. Patient 1, a 62-year old man who had undergone adrenalectomy for a 5 cm pheochromocytoma, was screened for type 2 multiple endocrine neoplasia (MEN 2) which showed elevated basal and post-intravenous calcium gluconate calcitonin levels. A fine needle aspiration biopsy (FNAB) confirmed the suspicion of MTC. The patient underwent total thyroidectomy and lymphadenectomy, and the histology showed C-cell hyperplasia with medullary microcarcinoma. Patient 2, a 57 years old woman, underwent total thyroidectomy for toxic multinodular goiter. Pre-operative FNAB had shown benign features, while basal calcitonin levels were only borderline increased. Final histology revealed medullary multifocal microcarcinoma. Genetic testing for RET protoncogene on DNA extracted from peripheral blood was performed in both patients and a missense variant on exon 2 (c.166C&#x0003e;A, p.L56M) was identified. To our knowledge, these are the first time two cases of MTC associated to RET p.L56M variant. Interestingly, one patient had also a pheochromocytoma suggesting a possible pathogenetic role of this variant in the genesis of MEN2A. While the association of this variant with MTC or MEN2A has been never reported, it has been described in association with Hirschsprung's disease.</p></abstract><kwd-group><kwd>medullary thyroid carcinoma</kwd><kwd>MEN2</kwd><kwd>RET</kwd><kwd>pheochromocytoma</kwd><kwd>L56M</kwd></kwd-group><counts><fig-count count="0"/><table-count count="1"/><equation-count count="0"/><ref-count count="17"/><page-count count="4"/><word-count count="3206"/></counts></article-meta></front><body><sec id="s1"><title>Background</title><p>Medullary thyroid carcinoma (MTC), originating from parafollicular C-cells, accounts for 5% of all thyroid cancers and can occur as sporadic (75% of cases) or hereditary (25%) disease (<xref rid="B1" ref-type="bibr">1</xref>). Germline <italic>RET</italic> proto-oncogene variants play a crucial pathogenetic role and are found in the majority of hereditary forms (98%). In fact, only few families with hereditary MTC do not show any germline variant (<xref rid="B2" ref-type="bibr">2</xref>). On the other hand, somatic <italic>RET</italic> variants are responsible for approximately 40% of cases of sporadic MTC, according to data of COSMIC database published in 2015 (<xref rid="B3" ref-type="bibr">3</xref>). The <italic>RET</italic> proto-oncogene, located on chromosome 10, codifies for a member of the tyrosine-kinase family receptors which is expressed on C cells, parathyroid glands, adrenal medulla and urogenital tract. In the hereditary forms, the causative role of the germline <italic>RET</italic> variants has been clearly demonstrated, and there appears to be a strict correlation between genotype and phenotype, leading to different degree of risk related to the aggressiveness of the tumor and the clinical syndrome [familiar medullary thyroid cancer (FMTC), and type 2A and type 2B multiple endocrine neoplasia (MEN) (<xref rid="B4" ref-type="bibr">4</xref>)]. The &#x0201c;classic MEN2A&#x0201d; phenotype is characterized by the concomitant occurrence of pheochromocytoma and primary hyperparathyroidism. In addition to the &#x0201c;classic MEN2A,&#x0201d; other forms associated with cutaneous lichen amyloidosis (<xref rid="B5" ref-type="bibr">5</xref>) and with Hirschsprung disease have been reported (<xref rid="B6" ref-type="bibr">6</xref>). MEN2A is primarily associated with variants in the <italic>RET</italic> gene causing substitution of cysteines at codons 609, 611, 618, and 620 in exon 10, and particularly with the Cys634Arg alteration in exon 11 (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>On the contrary, MEN2B, where MTC which is associated with pheochromocytoma and other additional clinical features (e.g., mucosal neuromas), is mostly associated with the Met918Thr variant in exon 16.</p><p>While genetic testing is mandatory whenever the familial form of MTC is suspected, germline <italic>RET</italic> testing may also be recommended in all patients with newly diagnosed C cell hyperplasia (CCH) or apparently sporadic MTC, since approximately 7% of patients, who would appear to have a &#x0201c;sporadic&#x0201d; form, in truth have an unsuspected germline variant in the <italic>RET</italic> proto-oncogene.</p><p>In the past decade, additional <italic>RET</italic> variants, unknown at the time of the International <italic>RET</italic> Consortium (<xref rid="B7" ref-type="bibr">7</xref>), have been discovered. These include very rare germline <italic>RET</italic> variants (<xref rid="B8" ref-type="bibr">8</xref>) often observed in a single affected member. However, the germline <italic>RET</italic> proto-oncogene variants identified during the past 20 years are localized in specific regions and involve eight exons (exons 5, 8, 10, 11, 13, 14, 15, 16) (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>We here report the first two cases of MTC associated with the variant of exon 2 of <italic>RET</italic> proto-oncogene causing the substitution of Leucine with Methionine at codon 56 (p.L56M; rs145633958), which, to the best of our knowledge, has not previously been reported in association to MTC. In one case, the diagnosis of MEN2A cannot be excluded, considering the concomitant occurrence of pheochromocytoma.</p><p>Interestingly, the above-mentioned variant has been described in association with Hirschsprung disease, which has been excluded in these two patients.</p></sec><sec id="s2"><title>Case presentation and description of laboratory investigations and diagnostic tests</title><p>Patient 1: A 62-year man came to our attention for an incidentally discovered right adrenal mass of 5 cm in diameter, detected during abdominal ultrasound evaluation for suspected nephrolithiasis. An abdominal computer tomography scan showed an adrenal mass suggestive of adrenal adenoma, without the typical radiological characteristics of pheochromocytoma.</p><p>The patient had hypertension which was well controlled by lercanidipine 10 mg/day. His family history was negative for endocrine disease.</p><p>Blood cortisol, aldosterone, adrenal androgens levels, and 24-h urinary catecholamine and metanephrines levels were normal. However, in consideration of the size of the tumor, the patient was referred for laparoscopic adrenalectomy. Surprisingly, final histology revealed a 55 mm pheochromocytoma. Because of the presence of bilateral thyroid micronodules (7 mm on right lobe and 9 mm on left lobe), serum calcitonin was measured, showing mildly elevated basal levels (20 pg/ml) and post i.v. calcium gluconate levels (296 and 366 pg/ml 2 and 3 min after the infusion, respectively). Fine needle aspiration biopsy (FNAB) performed on the left nodule confirmed the suspicion of MTC. The patient underwent total thyroidectomy and central neck dissection. Final pathology showed diffuse CCH and a 4 mm medullary microcarcinoma on the left nodule which previously had undergone FNAB, and no lymph node involvement.</p><p>Patient 2: A 58 years-old woman came to our attention for tachycardia. Laboratory evaluation showed mild hyperthyroidism and thyroid ultrasound revealed a multinodular goiter. Thyroid scintiscan confirmed the diagnosis of a toxic multinodular goiter, with a 2 cm hyperfunctioning left nodule. A FNAB evaluation performed on the most relevant non-hyperfunctioning nodule (15 mm on right lobe) showed was benign features (Thy 2). Serum calcitonin was borderline increased (13.2 pg/ml). Due to the symptoms of hyperthyroidism and dysphagia, the patient underwent total thyroidectomy and the final histology showed struma with CCH and medullary multifocal microcarcinoma (maximum diameter 6 mm on left lobe).</p><sec><title>Molecular analysis of <italic>RET</italic>-protoncogene</title><p>After obtaining informed consent, DNA was isolated from peripheral blood by a manual method (Roche Diagnostics, Basel, Switzerland, <ext-link ext-link-type="uri" xlink:href="http://www.roche.com/index.htm">http://www.roche.com/index.htm</ext-link>). Molecular analysis of the <italic>RET</italic> onco-gene was performed by sequencing of the coding region and exon-intron boundaries of the exons 2, 5, 8, 10, 11, 13&#x02013;16, as routinely performed in our laboratory. Primers used and the respective annealing temperatures are reported in Table <xref rid="T1" ref-type="table">1</xref>. PCR products were sequenced using the Big Dye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA, <ext-link ext-link-type="uri" xlink:href="http://www.appliedbiosystems.com/absite/us/en/home.html">http://www.appliedbiosystems.com/absite/us/en/home.html</ext-link>) in an automated sequencer ABI Prism 3500 Genetic Analyzer (Applied Biosystems).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Primers used for <italic>RET</italic> amplification and sequencing.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Oligo name</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Sequence (5&#x02032; 3&#x02032;)</bold></th><th valign="top" align="center" style="border-bottom: thin solid #000000;" rowspan="1" colspan="1"><bold>Annealing temperature</bold></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>(Ta) [&#x000b0;C]</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-2F</td><td valign="top" align="left" rowspan="1" colspan="1">GCT TCC CCT GTT TCC TTT TC</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-2R</td><td valign="top" align="left" rowspan="1" colspan="1">AGT GTC AGC GGC TGT GAT AA</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-5F</td><td valign="top" align="left" rowspan="1" colspan="1">CGT GCA GCA TTC TAA GGT CTC</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-5R</td><td valign="top" align="left" rowspan="1" colspan="1">CAT GTG TGT AGG GTG CTG CT</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-8F</td><td valign="top" align="left" rowspan="1" colspan="1">TGC TCC TGG CAC TGT CTT</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-8R</td><td valign="top" align="left" rowspan="1" colspan="1">TGG GGA CCA ATC ACT GTA CTC</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-1OF</td><td valign="top" align="left" rowspan="1" colspan="1">GGA CAC TGC CCT GGA AAT A</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-1OR</td><td valign="top" align="left" rowspan="1" colspan="1">ACT CGC CTC CCA GCA ATT T</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-11F</td><td valign="top" align="left" rowspan="1" colspan="1">ATA CGC AGC CTG TAC CCA CT</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">58</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-11R</td><td valign="top" align="left" rowspan="1" colspan="1">AAA TGG GGG CAG AAC ACA</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-13F</td><td valign="top" align="left" rowspan="1" colspan="1">CCA TCC TGA CCT GGT ATG GT</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-13R</td><td valign="top" align="left" rowspan="1" colspan="1">AAA CAG GGC AGG AGC AGT AG</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-14F</td><td valign="top" align="left" rowspan="1" colspan="1">GTC CAC CCC CTT ACT CAT TG</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-14R</td><td valign="top" align="left" rowspan="1" colspan="1">GTG GTG AGC CAT AGC ATG G</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-15F</td><td valign="top" align="left" rowspan="1" colspan="1">CCC CCG GCC CAG GTC TC</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-15R</td><td valign="top" align="left" rowspan="1" colspan="1">GCT CCA CTA ATC TTC GGT ATC TTT</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-16F</td><td valign="top" align="left" rowspan="1" colspan="1">TCT CCT TTA CCC CTC CTT CC</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RET-16R</td><td valign="top" align="left" rowspan="1" colspan="1">CAG TGA GGG GGT CAT TGC</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p><italic>Sanger</italic> sequencing revealed in both patients a missense variant on exon 2 (c.166C&#x0003e;A, p.L56M). This change from cytosine to adenine causes a substitution of Leucine with Methionine at codon 56. Genetic testing was performed also in first degree relatives and the same variant was found in the son of Patient 1, who is being followed with periodic ultrasonography and calcitonin measurements. In order to assess the frequency of this variant within our patient population, we also screened 100 healthy controls (200 alleles) by high-resolution melting analysis; these additional samples were used since the p.L56M was never found within the previous 250 patients referred to our laboratory with the suspicion of MEN2 or MTC. All screened subjects were from Northern, Central and Southern Italy. This screening resulted mute for the above-mentioned variant, indicating a frequency of &#x0003c;1%.</p></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>The <italic>RET</italic> proto-oncogene, located on the long arm of chromosome 10 (10q11.2), was first identified in 1985 by transfection of NIH 3T3 cells with human lymphoma DNA (<xref rid="B10" ref-type="bibr">10</xref>). The protein encoded by <italic>RET</italic> is a cellular tyrosine kinase transmembrane receptor that is divided into three domains: an N-terminal extracellular domain with cadherin-like regions, a cysteine-rich transmembrane domain, and a cytoplasmic domain with tyrosine kinase activity (<xref rid="B11" ref-type="bibr">11</xref>). The activation of <italic>RET</italic> stimulates multiple pathways promoting cell growth, proliferation, differentiation and survival (<xref rid="B4" ref-type="bibr">4</xref>).</p><p>Once the role of the mutated <italic>RET</italic> in the development of hereditary forms of MTC became clear, <italic>RET</italic> genetic screening was introduced into clinical practice (<xref rid="B8" ref-type="bibr">8</xref>), providing an important contribution in the diagnosis of MTC. In fact, before the introduction of the <italic>RET</italic> genetic screening test in clinical practice, the diagnosis of MTC was exclusively relying on FNAB and serum calcitonin measurements (<xref rid="B12" ref-type="bibr">12</xref>), which made the identification of making the identification of the familial forms quite challenging. Nowadays, genetic screening is aimed at the early identification of family members who carry the same mutation as the index case and to propose an early treatment considering of the degree of risk associated with the detected variant (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>Furthermore, the evidence that germline <italic>RET</italic> variants are present in about 6&#x02013;7% of &#x0201c;apparently sporadic&#x0201d; cases of MTC confirms the need to perform genetic screening in all patients with MTC (<xref rid="B8" ref-type="bibr">8</xref>). If a variant is found, the case is then reclassified as hereditary, and genetic screening of the first-degree relatives is strongly recommended (<xref rid="B9" ref-type="bibr">9</xref>). Following such recommendation, we performed genetic testing in our two patients following the diagnosis of &#x0201c;sporadic&#x0201d; MTC and, for the first time, a variant in exon 2 of RET was detected in association with MTC. Moreover, in Patient 1 the diagnosis of MEN2A cannot be ruled out, in consideration of the concomitant occurrence of MTC and pheochromocytoma.</p><p>As often reported for the &#x0201c;new&#x0201d; variants, the question is if the <italic>RET</italic> germline variant represents a driving force of MTC or if it is an incidental finding due to the increased use of screening (<xref rid="B14" ref-type="bibr">14</xref>). In literature, rare variants which cannot be considered to be &#x0201c;polymorphisms&#x0201d; and which have an uncertain role in the pathogenesis on MTC are described as variants of unknown significance (VUS) (<xref rid="B15" ref-type="bibr">15</xref>). In our case, the frequency of p.L56M variant in the general population is &#x0003c;1%, and cannot be considered a polymorphisms. Recently, the ClinVar database identified this mutation in the MEN2A. The clinical significance as been defined as &#x0201c;benign/likely benign,&#x0201d; because &#x0201c;it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease&#x0201d;<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref>. On the other hand, further studies are necessary to confirm the possible pathogenic role of this variant in MTC development: in fact, in clinical practice, genetic studies are often limited to exons 5, 8, 10, 11, 13, 14, 15, 16, where the majority of known <italic>RET</italic> pathogenic germline variant is localized. Whether the variant described by our group can be considered &#x0201c;pathogenic&#x0201d; in MTC or even in MEN2A is a hypothesis that needs to be confirmed. However, an interesting consideration is that this very same variant had previously been reported in association with Hirschsprung's disease, the congenital absence of ganglion cells in the submucosal and myenteric plexi of the gut. <italic>RET</italic> is the main gene implicated in this condition which, as mentioned earlier, represents a rare clinical feature of a MEN 2A clinical variant (<xref rid="B6" ref-type="bibr">6</xref>). Approximately 50% of familial cases of MTC and 7&#x02013;35% of non-familial cases of MTC have loss-of-function germline RET variants (<xref rid="B16" ref-type="bibr">16</xref>). The concomitant occurrence of Hirschsprung's disease and MEN 2 is a relatively rare event, due to the presence of a &#x0201c;Janus&#x0201d; variant in the <italic>RET</italic> proto-oncogene: these variants can act both as a gain-of-function and a loss-of-function variant. To date, four missense exon 10 <italic>RET</italic> variants have been implicated in this association, most frequently in codon C620 (mostly C620R and occasionally C620S, and rarely C620W), but also in other areas (e.g., C609, C611, and C618) (<xref rid="B6" ref-type="bibr">6</xref>). Common variants in the <italic>RET</italic> promoter (rs10900296; rs10900297), at a SOX10 binding site in intron 1 (rs2435357), and in exon 2 (rs1800858; c.135G&#x0003e;A;p.A45A) have also been associated with Hirschsprung's disease, suggesting that common as well as rare variants might influence the occurrence of Hirschsprung's disease (<xref rid="B17" ref-type="bibr">17</xref>). It is important to mention that the presence of Hirschsprung's disease in our two patients was excluded based on clinical evaluation. However, the association between MTC and exon 2 p.L56M variant, which in turn is also related with a disease involved in MEN 2 phenotype, underlines the possibility of a pathogenic role of p.L56M variant in MTC. These findings need further confirmatory results. Nevertheless, it is important to underline the importance to expand the genetic evaluation for <italic>RET</italic> germline variants in MTC or MEN2A patients also to exon 2, especially if genetic testing has excluded the presence of the more common variants located within other exons.</p></sec><sec id="s4"><title>Author contributions</title><p>RP, RL, GP, EC, AM, GC, AP, and SC have equally made their contribution to the work and approved it for publication.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><fn-group><fn id="fn0001"><p><sup>1</sup><ext-link ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/clinvar/variation/36723/evidence/">https://preview.ncbi.nlm.nih.gov/clinvar/variation/36723/evidence/</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>SA</given-names><suffix>Jr</suffix></name><name><surname>Pacini</surname><given-names>F</given-names></name><name><surname>Robinson</surname><given-names>BG</given-names></name><name><surname>Santoro</surname><given-names>M</given-names></name></person-group>. <article-title>Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update</article-title>. <source>J Clin Endocrinol Metab.</source> (<year>2013</year>) <volume>98</volume>:<fpage>3149</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2013-1204</pub-id><?supplied-pmid 23744408?><pub-id pub-id-type="pmid">23744408</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romei</surname><given-names>C</given-names></name><name><surname>Mariotti</surname><given-names>S</given-names></name><name><surname>Fugazzola</surname><given-names>L</given-names></name><name><surname>Taccaliti</surname><given-names>A</given-names></name><name><surname>Pacini</surname><given-names>F</given-names></name><name><surname>Opocher</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes</article-title>. <source>Eur J Endocrinol.</source> (<year>2010</year>) <volume>163</volume>:<fpage>301</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-10-0333</pub-id><?supplied-pmid 20516206?><pub-id pub-id-type="pmid">20516206</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romei</surname><given-names>C</given-names></name><name><surname>Ciampi</surname><given-names>R</given-names></name><name><surname>Elisei</surname><given-names>R</given-names></name></person-group>. <article-title>A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma</article-title>. <source>Nat Rev Endocrinol.</source> (<year>2016</year>) <volume>12</volume>:<fpage>192</fpage>&#x02013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1038/nrendo.2016.11</pub-id><?supplied-pmid 26868437?><pub-id pub-id-type="pmid">26868437</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torino</surname><given-names>F</given-names></name><name><surname>Paragliola</surname><given-names>RM</given-names></name><name><surname>Barnabei</surname><given-names>A</given-names></name><name><surname>Corsello</surname><given-names>SM</given-names></name></person-group>. <article-title>Medullary thyroid cancer: a promising model for targeted therapy</article-title>. <source>Curr Mol Med.</source> (<year>2010</year>) <volume>10</volume>:<fpage>608</fpage>&#x02013;<lpage>25</lpage>. <?supplied-pmid 20712590?><pub-id pub-id-type="pmid">20712590</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scapineli</surname><given-names>JO</given-names></name><name><surname>Ceolin</surname><given-names>L</given-names></name><name><surname>Punales</surname><given-names>MK</given-names></name><name><surname>Dora</surname><given-names>JM</given-names></name><name><surname>Maia</surname><given-names>AL</given-names></name></person-group>. <article-title>MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics</article-title>. <source>Fam Cancer</source> (<year>2016</year>) <volume>15</volume>:<fpage>625</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1007/s10689-016-9892-6</pub-id><?supplied-pmid 26920351?><pub-id pub-id-type="pmid">26920351</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>D</given-names></name><name><surname>Friedmacher</surname><given-names>F</given-names></name><name><surname>Puri</surname><given-names>P</given-names></name></person-group>. <article-title>The association between Hirschsprung's disease and multiple endocrine neoplasia type 2a: a systematic review</article-title>. <source>Pediatr Surg Int.</source> (<year>2014</year>) <volume>30</volume>:<fpage>751</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00383-014-3538-2</pub-id><?supplied-pmid 24972642?><pub-id pub-id-type="pmid">24972642</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Clayton</surname><given-names>D</given-names></name><name><surname>Schuffenecker</surname><given-names>I</given-names></name><name><surname>Lenoir</surname><given-names>G</given-names></name><name><surname>Cote</surname><given-names>G</given-names></name><name><surname>Gagel</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis</article-title>. <source>JAMA</source> (<year>1996</year>) <volume>276</volume>:<fpage>1575</fpage>&#x02013;<lpage>9</lpage>. <?supplied-pmid 8918855?><pub-id pub-id-type="pmid">8918855</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romei</surname><given-names>C</given-names></name><name><surname>Tacito</surname><given-names>A</given-names></name><name><surname>Molinaro</surname><given-names>E</given-names></name><name><surname>Agate</surname><given-names>L</given-names></name><name><surname>Bottici</surname><given-names>V</given-names></name><name><surname>Viola</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?</article-title>
<source>Clin Endocrinol.</source> (<year>2015</year>) <volume>82</volume>:<fpage>892</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/cen.12686</pub-id><?supplied-pmid 25440022?><pub-id pub-id-type="pmid">25440022</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elisei</surname><given-names>R</given-names></name><name><surname>Alevizaki</surname><given-names>M</given-names></name><name><surname>Conte-Devolx</surname><given-names>B</given-names></name><name><surname>Frank-Raue</surname><given-names>K</given-names></name><name><surname>Leite</surname><given-names>V</given-names></name><name><surname>Williams</surname><given-names>GR</given-names></name></person-group>. <article-title>2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer</article-title>. <source>Eur Thyroid J.</source> (<year>2013</year>) <volume>1</volume>:<fpage>216</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1159/000346174</pub-id><?supplied-pmid 24783025?><pub-id pub-id-type="pmid">24783025</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Ritz</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name></person-group>. <article-title>Activation of a novel human transforming gene, ret, by DNA rearrangement</article-title>. <source>Cell</source> (<year>1985</year>) <volume>42</volume>:<fpage>581</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 2992805?><pub-id pub-id-type="pmid">2992805</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arighi</surname><given-names>E</given-names></name><name><surname>Borrello</surname><given-names>MG</given-names></name><name><surname>Sariola</surname><given-names>H</given-names></name></person-group>. <article-title>RET tyrosine kinase signaling in development and cancer</article-title>. <source>Cytokine Growth Factor Rev.</source> (<year>2005</year>) <volume>16</volume>:<fpage>441</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.05.010</pub-id><?supplied-pmid 15982921?><pub-id pub-id-type="pmid">15982921</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elisei</surname><given-names>R</given-names></name><name><surname>Bottici</surname><given-names>V</given-names></name><name><surname>Luchetti</surname><given-names>F</given-names></name><name><surname>Di Coscio</surname><given-names>G</given-names></name><name><surname>Romei</surname><given-names>C</given-names></name><name><surname>Grasso</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders</article-title>. <source>J Clin Endocrinol Metab.</source> (<year>2004</year>) <volume>89</volume>:<fpage>163</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2003-030550</pub-id><?supplied-pmid 14715844?><pub-id pub-id-type="pmid">14715844</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Thyroid Association Guidelines Task Force</collab><name><surname>Kloos</surname><given-names>RT</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Evans</surname><given-names>DB</given-names></name><name><surname>Francis</surname><given-names>GL</given-names></name><name><surname>Gagel</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>Medullary thyroid cancer: management guidelines of the American Thyroid Association</article-title>. <source>Thyroid</source> (<year>2009</year>) <volume>19</volume>:<fpage>565</fpage>&#x02013;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1089/thy.2008.0403</pub-id><?supplied-pmid 19469690?><pub-id pub-id-type="pmid">19469690</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orgiana</surname><given-names>G</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Camedda</surname><given-names>A</given-names></name><name><surname>De Falco</surname><given-names>V</given-names></name><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Melillo</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure</article-title>. <source>J Clin Endocrinol Metab.</source> (<year>2004</year>) <volume>89</volume>:<fpage>4810</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2004-0365</pub-id><?supplied-pmid 15472167?><pub-id pub-id-type="pmid">15472167</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crockett</surname><given-names>DK</given-names></name><name><surname>Piccolo</surname><given-names>SR</given-names></name><name><surname>Ridge</surname><given-names>PG</given-names></name><name><surname>Margraf</surname><given-names>RL</given-names></name><name><surname>Lyon</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene</article-title>. <source>PLoS ONE</source> (<year>2011</year>) <volume>6</volume>:<fpage>e18380</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0018380</pub-id><?supplied-pmid 21479187?><pub-id pub-id-type="pmid">21479187</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attie</surname><given-names>T</given-names></name><name><surname>Pelet</surname><given-names>A</given-names></name><name><surname>Edery</surname><given-names>P</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Mulligan</surname><given-names>LM</given-names></name><name><surname>Amiel</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease</article-title>. <source>Hum Mol Genet.</source> (<year>1995</year>) <volume>4</volume>:<fpage>1381</fpage>&#x02013;<lpage>6</lpage>. <?supplied-pmid 7581377?><pub-id pub-id-type="pmid">7581377</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emison</surname><given-names>ES</given-names></name><name><surname>Garcia-Barcelo</surname><given-names>M</given-names></name><name><surname>Grice</surname><given-names>EA</given-names></name><name><surname>Lantieri</surname><given-names>F</given-names></name><name><surname>Amiel</surname><given-names>J</given-names></name><name><surname>Burzynski</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability</article-title>. <source>Am J Hum Genet.</source> (<year>2010</year>) <volume>87</volume>:<fpage>60</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2010.06.007</pub-id><?supplied-pmid 20598273?><pub-id pub-id-type="pmid">20598273</pub-id></mixed-citation></ref></ref-list></back></article>